Treatment of Subclinical Hypothyroidism in Pregnancy
Treat subclinical hypothyroidism in pregnancy with levothyroxine when TSH is elevated above trimester-specific reference ranges, targeting a TSH <2.5 mIU/L in the first trimester and <3 mIU/L in the second and third trimesters 1.
Treatment Threshold and Initiation
The 2012 Endocrine Society guidelines provide the clearest framework for treatment decisions. While the evidence for neurological benefit in offspring remains inconclusive, the potential benefits of preventing adverse obstetrical outcomes outweigh the minimal risks of levothyroxine therapy 1.
When to Treat:
- TSH above trimester-specific reference ranges with normal free T4 warrants treatment 1
- If trimester-specific ranges are unavailable, use TSH >4.0 mIU/L as the treatment threshold 2
- The older cutoff of 2.5 mIU/L has been replaced by this more conservative approach in recent consensus guidelines 2
- TSH >10 mIU/L always requires treatment regardless of antibody status 3
Starting Dose:
Begin with levothyroxine 50 mcg daily 2. However, newer evidence suggests a weight-based approach may be superior: after adjusting for confounders, weight-based dosing increased the odds of reaching target TSH within 4-8 weeks by more than 4-fold (OR 4.26) 4.
Target TSH Levels
Maintain tight control with specific targets:
- First trimester: TSH <2.5 mIU/L
- Second and third trimesters: TSH <3.0 mIU/L 1
Monitoring Strategy
Check TSH every 4-6 weeks during pregnancy to ensure targets are maintained 1. This frequent monitoring is critical because:
- Levothyroxine requirements typically increase by 30% or more by 4-6 weeks gestation 1
- Women with thyroid autoimmunity who are initially euthyroid remain at risk for developing hypothyroidism throughout pregnancy 1
Evidence Quality and Nuances
The recommendation to treat comes with important caveats about evidence quality. The landmark 2017 NEJM trial showed no improvement in childhood IQ at 5 years when levothyroxine was started between 8-20 weeks gestation 5. This negative trial has created controversy in the field 6.
However, the Endocrine Society guidelines acknowledge this limitation but still recommend treatment because:
- Retrospective studies and prospective studies in TPO-antibody positive women showed improved obstetrical outcomes with treatment 1
- The risks of appropriately managed levothyroxine are minimal 3
- Untreated overt hypothyroidism clearly causes serious fetal harm, and preventing progression is valuable 1
Recent 2024 evidence confirms obstetrical benefits when TSH >4 mIU/L, supporting the treatment approach 7.
Special Considerations
Pre-existing Hypothyroidism:
If diagnosed before pregnancy, adjust levothyroxine preconception to achieve TSH ≤2.5 mIU/L before attempting conception 1.
Postpartum Management:
Decrease levothyroxine to pre-pregnancy dose immediately after delivery in most women 1. However, do not automatically discontinue levothyroxine in all women treated for subclinical hypothyroidism during pregnancy—some may have underlying thyroid disease requiring ongoing treatment 2.
Common Pitfalls to Avoid
- Do not use non-pregnant reference ranges for TSH interpretation—pregnancy-specific or trimester-specific ranges are essential 1
- Do not delay treatment while waiting for repeat testing if TSH is clearly elevated
- Do not undertarget TSH—the goal is <2.5 mIU/L in first trimester, not just "normal range"
- Do not forget to increase the dose early in pregnancy for women already on levothyroxine—most need adjustment by 4-6 weeks gestation 1